Trial · NCT03209973
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 12 of 12
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Response Rate (ORR) | Tislelizumab | 87.1 | 95% Confidence Interval 77.0 to 93.9 | Percentage of Participants | |
| Progression-free Survival (PFS) | Tislelizumab | 31.5 | 95% Confidence Interval 16.53 to NA | Months | |
| Duration of Response (DOR) | Tislelizumab | 31.3 | 95% Confidence Interval 20.73 to NA | Months | |
| Rate of Complete Response (CRR) | Tislelizumab | 67.1 | 95% Confidence Interval 54.9 to 77.9 | Percentage of participants | |
| Time to Response (TTR) | Tislelizumab | 12.0 | Full Range 11.86 to 12.29 | Weeks | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Tislelizumab | Participants with At least one TEAE | 68 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Tislelizumab | SAE | 18 | Participants | |
| Number of Participants With Significant Changes in Clinical Laboratory Results | Tislelizumab | 0 | Participants | ||
| Number of Participants With Significant Changes in Electrocardiograms | Tislelizumab | Postbaseline corrected QT interval > 450 msec | 0 | Participants | |
| Number of Participants With Significant Changes in Electrocardiograms | Tislelizumab | ≥ 1 postbaseline electrocardiogram | 21 | Participants | |
| Number of Participants With Significant Changes in Electrocardiograms | Tislelizumab | Increase corrected QT interval of ≤ 30 msec | 18 | Participants | |
| Number of Participants With Significant Changes in Electrocardiograms | Tislelizumab | Increase > 30 msec but ≤ 60 msec corrected QT interval | 4 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03209973/results